Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Robert Bindert Huizinga, insider at Aurinia Pharmaceuticals
Robert Bindert Huizinga Insider Alerts

Get notified the next time Robert Bindert Huizinga buys or sells Aurinia Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Robert Bindert Huizinga Insider Information

Rob, previously Executive Vice President of Corporate Development, has more than 25 years of drug development expertise and also one of the longest histories in the Company working with voclosporin. Rob developed the global clinical program of voclosporin since its inception at Isotechnika prior to its merger with Aurinia in 2013, along with raising development funds in the public markets. He continues to work with the Clinical Development team since the merger through the LN NDA. Rob is leading the Research group who are not only helping us understand the impact of calcineurin inhibition beyond immunosuppression, but the pre-clinical evaluation of in-licensed compounds. Before joining the industry, Rob was a Clinical Investigator and Epidemiologist at the University of Alberta Division of Nephrology & Immunology, where he was involved in more than 60 clinical trials from Phase I through Phase IV and the successful development of numerous compounds including CellCept®, Neoral®, Prograf®, Aranesp® and Simulect®. Rob has numerous articles published in leading medical journals in the areas of pharmacology, immunology, transplantation, and autoimmune diseases.

Rob holds an M.Sc. in Medicine (Epidemiology) from the University of Alberta, a Ph.D. in Organizational Leadership from Regent University, is certified in Nephrology, and a member of Sigma Theta Tau (Honor Society of Nursing). He holds a certificate in leadership from EQUIP Leadership.

What is Robert Bindert Huizinga's net worth?

The estimated net worth of Robert Bindert Huizinga is at least $2.49 million as of September 10th, 2021. Dr. Huizinga owns 133,592 shares of Aurinia Pharmaceuticals stock worth more than $2,494,163 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Huizinga may own. Learn More.

How old is Robert Bindert Huizinga?

Dr. Huizinga is currently 56 years old. There are 5 older executives and no younger executives at Aurinia Pharmaceuticals. Learn More.

How do I contact Robert Bindert Huizinga?

The corporate mailing address for Dr. Huizinga and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at [email protected]

Has Robert Bindert Huizinga been buying or selling shares of Aurinia Pharmaceuticals?

During the last quarter, Robert Bindert Huizinga has sold $3,867,500.00 of Aurinia Pharmaceuticals stock. Most recently, Robert Bindert Huizinga sold 130,000 shares of the business's stock in a transaction on Monday, October 25th. The shares were sold at an average price of $29.75, for a transaction totalling $3,867,500.00.

Who are Aurinia Pharmaceuticals' active insiders?

Aurinia Pharmaceuticals' insider roster includes Matthew Donley (VP), Peter Greenleaf (CEO), Robert Huizinga (EVP), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider).

Are insiders buying or selling shares of Aurinia Pharmaceuticals?

In the last twelve months, Aurinia Pharmaceuticals insiders bought shares 6 times. They purchased a total of 20,625 shares worth more than $225,483.75. In the last twelve months, insiders at the biotechnology company sold shares 14 times. They sold a total of 552,500 shares worth more than $14,228,500.00. The most recent insider tranaction occured on November, 11th when insider Michael Robert Martin sold 40,000 shares worth more than $1,160,400.00. Insiders at Aurinia Pharmaceuticals own 3.1 % of the company.

Information on this page was last updated on 11/11/2021.

Robert Bindert Huizinga Insider Trading History at Aurinia Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2021Sell130,000$29.75$3,867,500.00View SEC Filing Icon  
9/21/2021Sell32,500$23.99$779,675.00View SEC Filing Icon  
9/14/2021Sell22,500$21.75$489,375.00View SEC Filing Icon  
9/10/2021Sell10,000$19.80$198,000.00133,592View SEC Filing Icon  
See Full Table

Robert Bindert Huizinga Buying and Selling Activity at Aurinia Pharmaceuticals

This chart shows Robert Bindert Huizinga's buying and selling at Aurinia Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Read More

Today's Range

Now: $18.67
Low: $18.40
High: $21.24

50 Day Range

MA: $24.52
Low: $17.78
High: $33.08

2 Week Range

Now: $18.67
Low: $9.72
High: $33.97

Volume

6,643,845 shs

Average Volume

4,966,271 shs

Market Capitalization

$2.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!